Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 64.07 is 217% above its 5-year average of 20.24, near the high end of its 5-year range (8.00–64.07).
As of the fiscal period ended Tuesday, June 30, 2026. 61.32% above its 12-month average of 39.72.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 64.07.
QUICK RATIO (ACID-TEST)
64.07
QUICK RATIO (ACID-TEST) AVG TTM
39.72
QUICK RATIO (ACID-TEST) AVG 3Y
23.70
QUICK RATIO (ACID-TEST) AVG 5Y
20.24
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+61.32%
CURRENT VS 3Y AVG
+170.40%
CURRENT VS 5Y AVG
+216.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+1812.63%
vs the sector median at left
Enliven Therapeutics, Inc.
Market Cap
$3.03B
Quick Ratio (Acid-Test)
64.07
TTM Avg
39.72
3Y Avg
23.70
5Y Avg
20.24
Market Cap
$3.06B
Quick Ratio (Acid-Test)
8.32
TTM Avg
8.81
3Y Avg
8.76
5Y Avg
9.71
Market Cap
$2.99B
Quick Ratio (Acid-Test)
2.67
TTM Avg
3.48
3Y Avg
6.28
5Y Avg
8.36
Market Cap
$3.12B
Quick Ratio (Acid-Test)
12.12
TTM Avg
10.47
3Y Avg
8.53
5Y Avg
7.00
Market Cap
$2.88B
Quick Ratio (Acid-Test)
12.02
TTM Avg
18.93
3Y Avg
12.46
5Y Avg
15.83
Market Cap
$3.19B
Quick Ratio (Acid-Test)
3.17
TTM Avg
4.10
3Y Avg
7.42
5Y Avg
12.78
Market Cap
$2.77B
Quick Ratio (Acid-Test)
6.07
TTM Avg
7.05
3Y Avg
8.10
5Y Avg
8.04
Market Cap
$3.31B
Quick Ratio (Acid-Test)
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | 64.07 | 39.72 | 23.70 | 20.24 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 8.32 | 8.81 | 8.76 | 9.71 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 2.67 | 3.48 | 6.28 | 8.36 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 12.12 | 10.47 | 8.53 | 7.00 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 12.02 | 18.93 | 12.46 | 15.83 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 3.17 | 4.10 | 7.42 | 12.78 |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 6.07 | 7.05 | 8.10 | 8.04 |
| CareDx, Inc (CDNA)vs › | $3.30B | 4.51 | 3.14 | 3.73 | 4.01 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 4.72 | 21.21 | 17.30 | 19.05 |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 3.19 | 2.81 | 2.79 | 3.25 |
Quick Ratio
64.07
Excludes inventory
Current Ratio
64.07
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 64.07 |
| 2026-03-31 | 40.32 |
| 2025-12-31 | 28.66 |
| 2025-09-30 | 32.95 |
| 2025-06-30 | 32.58 |
| 2025-03-31 | 21.06 |
| 2024-12-31 | 19.99 |
| 2024-09-30 | 17.44 |
| 2024-06-30 | 14.39 |
| 2024-03-31 | 13.47 |
| 2023-12-31 | 10.28 |
| 2023-09-30 | 22.24 |
| 2023-06-30 | 30.96 |
| 2023-03-31 | 27.23 |
| 2022-12-31 | 8.00 |
| 2022-09-30 | 10.59 |
| 2022-06-30 | 19.46 |
| 2022-03-31 | 10.87 |
| 2021-12-31 | 19.24 |
| 2021-09-30 | 14.75 |
| 2021-06-30 | 10.23 |
| 2021-03-31 | 14.60 |
| 2020-12-31 | 14.47 |
| 2020-09-30 | 18.78 |
| 2020-06-30 | 22.81 |
| 2020-03-31 | 22.19 |
| 2019-12-31 | 7.29 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
